Brian Abrahams
Stock Analyst at RBC Capital
(1.69)
# 2,789
Out of 4,827 analysts
445
Total ratings
33.33%
Success rate
-6.97%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $87 → $58 | $36.22 | +60.13% | 34 | May 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $57 → $58 | $44.60 | +30.04% | 20 | May 7, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $65 → $58 | $6.46 | +797.83% | 8 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $420 → $423 | $429.44 | -1.50% | 52 | May 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $137 → $145 | $117.10 | +23.83% | 19 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $11 → $13 | $9.93 | +30.92% | 18 | May 6, 2025 | |
| BIIB Biogen | Maintains: Outperform | $217 → $205 | $118.66 | +72.77% | 36 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,051 → $943 | $534.97 | +76.27% | 31 | Apr 30, 2025 | |
| INCY Incyte | Maintains: Sector Perform | $64 → $67 | $59.39 | +12.81% | 21 | Apr 30, 2025 | |
| LEGN Legend Biotech | Reiterates: Outperform | $84 | $31.54 | +166.33% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $21 | $10.34 | +103.09% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $38.50 | +74.03% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $10.56 | +193.70% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $3 | $1.41 | +113.52% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $0.67 | +497.19% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $20 | $7.45 | +168.46% | 10 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $6.00 | +650.00% | 11 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $84 → $90 | $96.99 | -7.21% | 31 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $109.30 | +30.84% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $18.69 | +114.02% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $20 → $1.5 | $1.14 | +31.58% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $3.85 | +705.19% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $1.5 | $0.40 | +275.47% | 5 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $48 → $2 | $1.36 | +47.06% | 11 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Perform | $4 | $6.54 | -38.84% | 21 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $25.37 | +18.25% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $35.02 | +57.05% | 13 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $7.71 | +55.64% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $6.19 | +255.70% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $5.35 | +180.37% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.40 | +542.86% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $41.40 | -20.29% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $35.58 | - | 4 | Dec 4, 2017 |
Sarepta Therapeutics
May 7, 2025
Maintains: Sector Perform
Price Target: $87 → $58
Current: $36.22
Upside: +60.13%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $57 → $58
Current: $44.60
Upside: +30.04%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $65 → $58
Current: $6.46
Upside: +797.83%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $420 → $423
Current: $429.44
Upside: -1.50%
Neurocrine Biosciences
May 6, 2025
Maintains: Outperform
Price Target: $137 → $145
Current: $117.10
Upside: +23.83%
BioCryst Pharmaceuticals
May 6, 2025
Reiterates: Outperform
Price Target: $11 → $13
Current: $9.93
Upside: +30.92%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $217 → $205
Current: $118.66
Upside: +72.77%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Outperform
Price Target: $1,051 → $943
Current: $534.97
Upside: +76.27%
Incyte
Apr 30, 2025
Maintains: Sector Perform
Price Target: $64 → $67
Current: $59.39
Upside: +12.81%
Legend Biotech
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $31.54
Upside: +166.33%
Apr 1, 2025
Reiterates: Outperform
Price Target: $21
Current: $10.34
Upside: +103.09%
Mar 18, 2025
Initiates: Outperform
Price Target: $67
Current: $38.50
Upside: +74.03%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $10.56
Upside: +193.70%
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.41
Upside: +113.52%
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $0.67
Upside: +497.19%
Feb 21, 2025
Maintains: Sector Perform
Price Target: $24 → $20
Current: $7.45
Upside: +168.46%
Feb 20, 2025
Reiterates: Outperform
Price Target: $45
Current: $6.00
Upside: +650.00%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $84 → $90
Current: $96.99
Upside: -7.21%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $109.30
Upside: +30.84%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $18.69
Upside: +114.02%
Jan 10, 2025
Downgrades: Sector Perform
Price Target: $20 → $1.5
Current: $1.14
Upside: +31.58%
Jan 9, 2025
Reiterates: Outperform
Price Target: $31
Current: $3.85
Upside: +705.19%
Dec 20, 2024
Maintains: Sector Perform
Price Target: $4 → $1.5
Current: $0.40
Upside: +275.47%
Dec 20, 2024
Downgrades: Sector Perform
Price Target: $48 → $2
Current: $1.36
Upside: +47.06%
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $6.54
Upside: -38.84%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $25.37
Upside: +18.25%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $35.02
Upside: +57.05%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $7.71
Upside: +55.64%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $6.19
Upside: +255.70%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $5.35
Upside: +180.37%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.40
Upside: +542.86%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $41.40
Upside: -20.29%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $35.58
Upside: -